药学学报, 2018, 53(4): 495-499
引用本文:
姜剑伟, 王蕊, 李燕. Sab蛋白的研究进展[J]. 药学学报, 2018, 53(4): 495-499.
JIANG Jian-wei, WANG Rui, LI Yan. Research advances in study of Sab protein[J]. Acta Pharmaceutica Sinica, 2018, 53(4): 495-499.

Sab蛋白的研究进展
姜剑伟, 王蕊, 李燕
中国医学科学院、北京协和医学院药物研究所, 创新药物非临床药物代谢及PK/PD研究北京市重点实验室, 北京 100050
摘要:
Sab(SH3 domain-binding protein that preferentially associates with Btk)蛋白,又称SH3BP5(SH3 domain-binding protein 5)蛋白,是具有调控线粒体生理功能的线粒体外膜支架蛋白,可与酪氨酸激酶Btk(Bruton's tyrosine kinase)、丝氨酸-苏氨酸激酶JNKs(c-Jun amino-terminal kinases)及p38γ结合,从而调控B细胞抗原受体和线粒体JNK、p38γ信号通路,参与B细胞生长发育和线粒体信号转录等重要生理过程。调节Sab蛋白的表达可改善Btk、JNKs及p38γ异常引起的相关疾病,如神经系统疾病和肝损伤等,因而Sab蛋白有望成为药物研发的潜在靶点。本文简述了Sab蛋白的结构、功能及与弥漫大B细胞淋巴瘤、神经系统疾病和急性肝损伤的关系,旨在为药物研发提供新的思路和理论依据。
关键词:    Sab蛋白      结构      功能      靶点      JNK     
Research advances in study of Sab protein
JIANG Jian-wei, WANG Rui, LI Yan
Beijing Key Laboratory of Non-Clinical Drug Metabolism and PK/PD Study, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
Abstract:
Sab (SH3 domain-binding protein that preferentially associates with Btk) that is also called SH3BP5 (SH3 domain-binding protein 5), is a scaffold protein on mitochondrial outer membrane in the modulation of mitochondrial function. Sab not only combines with the tyrosine kinase Btk (Bruton's tyrosine kinase), but also binds to the serine threonine kinase JNKs (c-Jun amino-terminal kinases) and p38γ. Thus Sab can regulate B cell antigen receptor, mitochondrial JNK and p38γ signaling pathway, which is associated with the critical physiological function, such as B-cell development and differentiation and regulation of mitochondrial signaling transcription. Inhibition or induction on the expression of Sab can ameliorate the diseases arising from the abnormal level of Btk, JNKs and p38γ, such as nervous system diseases and liver injury. Therefore, Sab could be expected as a new target for drug development. In this article, we provide an overview of the structure and functions of Sab and its relationship to diseases of diffuse large B-cell lymphoma, nervous system diseases and liver injury, aiming to provide new ideas and theoretical basis for the development of new drugs.
Key words:    Sab    structure    function    target    JNK   
收稿日期: 2017-10-25
DOI: 10.16438/j.0513-4870.2017-1054
基金项目: 中国医学科学院医学与健康科技创新工程经费资助(2017-I2M-1-010).
通讯作者: 李燕,Tel:86-10-63165172,E-mail:yanli@imm.ac.cn
Email: yanli@imm.ac.cn
相关功能
PDF(184KB) Free
打印本文
0
作者相关文章
姜剑伟  在本刊中的所有文章
王蕊  在本刊中的所有文章
李燕  在本刊中的所有文章

参考文献:
[1] Matsushita M, Yamadori T, Kato S, et al. Identification and characterization of a novel SH3-domain binding protein, Sab, which preferentially associates with Bruton's tyrosine kinase (BtK)[J]. Biochem Biophys Res Commun, 1998, 245:337-343.
[2] Wiltshire C, Matsushita M, Tsukada S, et al. A new c-Jun N-terminal kinase (JNK)-interacting protein, Sab (SH3BP5), associates with mitochondria[J]. Biochem J, 2002, 367:577-585.
[3] Court NW, Kuo I, Quigley O, et al. Phosphorylation of the mitochondrial protein Sab by stress-activated protein kinase 3[J]. Biochem Biophys Res Commun, 2004, 319:130-137.
[4] Baba Y, Matsushita M, Matsuda Y, et al. Assignment of SH3BP5/Sh3bp5 encoding Sab, an SH3 domain-binding protein which preferentially associates with Bruton's tyrosine kinase, to human chromosome 1q43 and mouse chromosome 14B by in situ hybridization[J]. Cytogenet Cell Genet, 1999, 87:221-222.
[5] Wiltshire C, Gillespie DAF, May GHW. Sab (SH3BP5), a novel mitochondria-localized JNK-interacting protein[J]. Biochem Soc Trans, 2004, 32:1075-1077.
[6] Akinleye A, Chen Y, Mukhi N, et al. Ibrutinib and novel BTK inhibitors in clinical development[J]. J Hematol Oncol, 2013, 6:59.
[7] Yamadori T, Baba Y, Matsushita M, et al. Bruton's tyro-sine kinase activity is negatively regulated by Sab, the Btk-SH3 domain-binding protein[J]. Proc Natl Acad Sci U S A, 1999, 96:6341-6346.
[8] Takeshita Y, Hashimoto Y, Nawa M, et al. SH3-binding protein 5 mediates the neuroprotective effect of the secreted bioactive peptide humanin by inhibiting c-Jun NH2-terminal kinase[J]. J Biol Chem, 2013, 288:24691-24704.
[9] Win S, Than TA, Min RWM, et al. JNK mediates mouse liver injury through a novel Sab (SH3BP5) dependent pathway leading to inactivation of intramitochondrial Src[J]. Hepatology, 2016, 63:1987-2003.
[10] Chambers JW, LoGrasso PV. Mitochondrial c-Jun N-terminal kinase (JNK) signaling initiates physiological changes resulting in amplification of reactive oxygen species generation[J]. J Biol Chem, 2011, 286:16052-16062.
[11] Win S, Than TA, Fernandezcheca JC, et al. JNK interaction with Sab mediates ER stress induced inhibition of mitochondrial respiration and cell death[J]. Cell Death Dis, 2014, 5:e989.
[12] Win S, Than TA, Han D, et al. c-Jun N-terminal kinase (JNK)-dependent acute liver injury from acetaminophen or tumor necrosis factor (TNF) requires mitochondrial Sab protein expression in mice[J]. J Biol Chem, 2011, 286:35071-35078.
[13] Chambers JW, Cherry L, Laughlin JD, et al. Selective inhibition of mitochondrial JNK signaling achieved using peptide mimicry of the Sab kinase interacting motif-1(KIM1)[J]. ACS Chem Biol, 2011, 6:808-818.
[14] Kobayashi K, Yamaguchi M, Miyazaki K, et al. Expres-sions of SH3BP5, LMO3, and SNAP25 in diffuse large B-cell lymphoma cells and their association with clinical features[J]. Cancer Med, 2016, 5:1802-1809.
[15] Sodero AO, Rodriguezsilva M, Salio C, et al. Sab is differentially expressed in the brain and affects neuronal activity[J]. Brain Res, 2017, 1670:76-85.
[16] Chambers JW, Howard S, LoGrasso PV. Blocking c-Jun N-terminal kinase (JNK) translocation to the mitochondria prevents 6-hydroxydopamine-induced toxicity in vitro and in vivo[J]. J Biol Chem, 2013, 288:1079-1087.
[17] Nijboer CH, Bonestroo HJC, Zijlstra J, et al. Mitochondrial JNK phosphorylation as a novel therapeutic target to inhibit neuroinflammation and apoptosis after neonatal ischemic brain damage[J]. Neurobiol Dis, 2013, 54:432-444.
[18] Win S, Than TA, Le BHA, et al. Sab (Sh3bp5) dependence of JNK mediated inhibition of mitochondrial respiration in palmitic acid induced hepatocyte lipotoxicity[J]. J Hepatol, 2015, 62:1367-1374.
相关文献:
1.陈金晶, 赵晓丽, 王真, 陈琳峰.含溴结构域和额外终端域家族蛋白——表观遗传领域的新型治疗靶点[J]. 药学学报, 2017,52(8): 1209-1215
2.张友文, 张丹, 孙华.次黄嘌呤脱氢酶的基本功能及作为药物靶点的应用[J]. 药学学报, 2014,49(3): 285-292
3.孙 巍, 林 珩, 花 芳, 胡卓伟.治疗性抗体: 炎性免疫性疾病治疗的新选择[J]. 药学学报, 2012,47(10): 1306-1316